Projects funded by the NCN
In search for molecular targets to overcome doxorubicin resistance in triple-negative breast cancer with the use of innovative drug carriers and combination therapy
2021/41/N/NZ7/02530
Keywords:
doxorubicin triple-negative breast cancer breast cancer drug carrier combination therapy drug resistance
Descriptors:
- NZ7_014:
- NZ3_001:
- NZ1_002:
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Narodowy Instytut Leków
woj. mazowieckie
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 20 - announced on 2021-03-15
Amount awarded: 210 000 PLN
Project start date (Y-m-d): 2022-01-10
Project end date (Y-m-d): 2026-01-09
Project duration:: 48 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (3)
- Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer modelsAuthors:A. Pogorzelska, M. Świtalska, J. Wietrzyk, M. Mazur, M. Milczarek, K. Medyńska, K. WiktorskaAcademic press:Scientific reports (rok: 2024, tom: 14, strony: 16016), Wydawca: Springer NatureStatus:PublishedDOI:10.1038/s41598-024-65455-w - link to the publication
- Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal modelAuthors:Pogorzelska, A., Mazur, M., Świtalska, M., Wietrzyk, J., Sigorski, D., Fronczyk, K., Wiktorska, K.Academic press:Biomedicine & pharmacotherapy (rok: 2023, tom: 161, strony: 11), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.biopha.2023.114490 - link to the publication
- Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal modelAuthors:Pogorzelska, A., Mazur, M., Świtalska, M., Wietrzyk, J., Sigorski, D., Fronczyk, K., Wiktorska, K.Academic press:Biomedicine & pharmacotherapy (rok: 2023, tom: 161, strony: 11), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.biopha.2023.114490 - link to the publication